Patrick Kellens

Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The private company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million.

Fordham University provides college and university. It offers undergraduate colleges and graduate & professional schools. The company was founded in 1841 and is headquartered in Bronx, NY.

Ashfield Healthcare GmbH engages in the provision of human resources for the marketing and sale of pharmaceutical products, including other products and services in the healthcare industry. It specializes in the preparation for product launches, accessing new target groups, and repositioning of proven products. The company was founded in 1999 and is headquartered in Hirschberg, Germany.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.

Part of Laboratoires S.M.B. SA, SMB Technology is a Belgian company that provides IT consulting services. The private company is based in Brussels, Belgium. The CEO of the company is Caroline Baudier.

Uteron Pharma SA is engaged in the research and development of controlled release devices. The firms products Levosert and Diafert provide pharmaceutical solutions for women's health. The company was founded by Stijn van Rompay in 2010 and is headquartered in Grâce-Hollogne, Belgium.

Part of InQpharm Group, Neem Biotech Ltd. is a British biotech company focused on developing groundbreaking ways of defeating big health challenges. The private company is based in St. Mellons, UK. Leveraging their unique position in antimicrobial R&D, they have expertise in drug discovery. Neem Biotech was acquired by InQpharm Group on August 09, 2012.

Novalon SA manufactures pharmaceutical products. It focuses on the development of therapeutically equivalent generic products that are complex to develop and manufacture. The firm develops the projects Zoreline and Myring, which are therapeutic equivalents to branded products. The company is headquartered in Liege, Belgium.

Part of AbbVie, Inc., Odyssea Pharma SPRL is a pharmaceutical development and Belgian production company. The private company is based in Grâce-Hollogne, Belgium.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

Zaluvida Holdings Pte Ltd. provides solutions that improve the lives of livestock and protect the planet. Zaluvida Holdings is based in Singapore, Singapore. The Singaporean company also offers products that help pets stay healthier. The private company's focus is on developing new alternatives to antibiotics that can benefit farmers. and has subsidiaries in Switzerland, Germany, and Malaysia.

Hedera 22 SCRL supplies and leases computers and office equipment. The company was founded by Sébastien Rigali, Pierre Tocquin, Marc Hanikenne and Denis Baurain on May 25, 2015 and is headquartered in Esneux, Belgium.

AuXin Surgery SA develops, manufactures, and supplies combined medical devices for non-invasive surgery. The private company is based in Ottignies-Louvain-la-Neuve, Belgium. The Belgian company was founded in 2014 by Philippe Capart, Cecile Capart, Herve Capart, Carlo Zini, and Gilles Capart. The CEO is Benoît Verjans.

Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020.

Odix SA is a Belgian cybersecurity company that specializes in developing and marketing advanced anti-malware tools for enterprises of all sizes. The company is based in Thimister-Clermont, Belgium and was founded in 2020. The company's patented content disarm and reconstruction (TrueCDR™) technology is trusted by companies in various sectors, including industrial, finance, insurance, and government. The CEO is Valérie Gordenne.